Wormwood (Artemisia absinthium) and Crohn's disease

What 2 graded rows on wormwood (artemisia absinthium) agree on for Crohn's disease, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Wormwood (Artemisia absinthium) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Wormwood (Artemisia absinthium) page, with its PubMed record.

Supplement

Wormwood (Artemisia absinthium) Choose another

2 rows · 60 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade D, is a randomized trial of 40 people (2007) and found an improvement.

The rows run from 20 to 40 people, published from 2007 to 2010: 2 single studies.

2 improved

Grade DCrohn's disease activity while steroids were tapered · Improved
RCT · n 40 · 2007 · Adults with Crohn's disease on 40 mg/day prednisone-equivalent or less (5 German sites)
500 mg three times daily · 10 weeks, followed to week 20
After 8 weeks, 13 of 20 (65%) on wormwood had near-complete remission vs none on placebo; steroids had to be restarted in 2 of 20 vs 16 of 20.
Row on the Wormwood (Artemisia absinthium) page · PubMed 17240130 (opens PubMed)
Grade DCrohn's disease activity and TNF-alpha · Improved
RCT · n 20 · 2010 · Adults with active Crohn's disease (CDAI 200 or more) on stable therapy
750 mg three times daily · 6 weeks
Serum TNF-alpha fell from 24.5 to 8.0 pg/ml vs 25.7 to 21.1 in controls; 8 of 10 reached remission vs 2 of 10.
Row on the Wormwood (Artemisia absinthium) page · PubMed 19962291 (opens PubMed)